Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044382
Status:
COMPLETED
Last Update Posted:
2019-11-08
First Post:
2002-08-27
Brief Title:
Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
A Phase II Open Label Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To estimate the percent of patients with myelodysplastic syndromes MDS who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None